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Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive
injury response that promotes dormancy escape and tumor recurrence. We hypothesized that these events could be altered
by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation. Preoperative, but not
postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized
proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term
survival. Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated
by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway. Preoperative
stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell
responses. Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced
dormancy escape. Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous
resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.

Introduction

Cancer treatment is a double-edged sword, as surgery (including
biopsy), chemotherapy, or radiation can induce tumor-dormancy
escape and subsequent metastatic outgrowth by impairing
tumor-specific immunity through inflammation-mediated growth
signals and loss of resolution of inflammation (1–16). Even anesthetics can impair inflammation resolution (17). Recent results
show that chemotherapy-generated cell death can paradoxically
promote tumor growth via the release of proinflammatory and
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proangiogenic cytokines (9, 10, 18). Moreover, a preoperative
cycle of chemotherapy can stimulate proinflammatory cytokines
after cancer surgery (19), and surgical wounding may impair the
efficacy of chemotherapy (20).
In the treatment of locoregional disease, the perioperative
period offers a unique window for curbing the risk of metastatic
growth and relapse (2, 4, 21–27). For instance, a bimodal pattern
of recurrence for early stage breast and lung cancers suggests that
surgery potentiates the metastatic process by inducing tumor-
dormancy escape of micrometastatic lesions (28–30). Micro
metastases present in cancer patients at the time of surgery are
associated with reduced survival (31). Moreover, surgery can
promote metastasis, not simply by mechanical dissemination of
cancer cells, but also by stimulation of systemic inflammation and
surgery-associated immunosuppression, resulting in outgrowth of
dormant cancer cells at distant sites (2).
Over 30% of healthy individuals harbor microscopic dormant
cancers (32), and noncancer surgery and anesthesia may promote
the growth of such occult microtumors (33). Importantly, retrospective analyses of tumor recurrence in patients undergoing breast cancer surgery revealed that preoperative administration of ketorolac

RESEARCH ARTICLE

The Journal of Clinical Investigation  
was associated with a marked reduction of recurrence and mortality after surgery (34). However, ketorolac did not exhibit cancer-preventive activity when administered postoperatively, which is when
NSAIDs are routinely administered for pain management (34).
Preoperative ketorolac increased blood CD4+ T cells in patients
undergoing tumor resection, potentially reversing surgery-induced
immunosuppression during the perioperative period (35).
Chronic inflammation has been associated with tumor-promoting activity (36, 37), in part due to a deficit in the resolution
of inflammation (12). Cancer therapies have focused on blocking the production of COX-2–derived eicosanoids to suppress
tumor-promoting inflammation (38). However, COX-2 is also host
protective, as its metabolite, prostaglandin E2 (PGE2), plays a role
in the resolution of inflammation in the chronic phase (39). Specifically, tight regulation of the temporal pattern of PGE2 release
is critical for activating the class switching of lipid mediators from
production of inflammatory mediators to that of proresolution signals through specialized proresolving mediators (SPMs) (40, 41).
PGE2 released by dead cells negatively regulates an inflammatory response activated by damage-associated molecular patterns,
which may also contribute to the proresolution activity of PGE2
(42). Other COX-2–derived prostaglandins of the D2 and J2 series
generate lipid mediators that accelerate resolution of inflammation and control endogenous inflammation (12). Thus, COX-2
inhibitors may be “resolution toxic,” as they suppress the production of these prostaglandins (12, 39, 40, 43) and may worsen therapy-induced cancer progression.
PGE2 also exhibits immunosuppressive activity, stimulates
regulatory T cells, inhibits antigen presentation, and suppresses
NK cells (36, 38). Although these functions demonstrate the role
of PGE2 in the resolution phase of inflammation, they may inhibit
antitumor immunity, hence promoting tumor escape (36). The dual
activities of eicosanoids may explain the biphasic dose-dependent
or paradoxical relationship between chronic use of NSAIDs and
cancer risk (44). Given the opposing roles of eicosanoids, NSAIDs
that are intended to block tumor-promoting inflammation may
counter the resolution process and thus impose an inherent limitation of efficacy. Thus, simultaneously blocking the proinflammatory response and activating endogenous resolution programs may
control cancer therapy–stimulated inflammation.
The SPM superfamily consists of potent immunoresolvent
agonists derived from omega-3 fatty acids (e.g., resolvins, protectins, and maresins) as well as arachidonic acid (e.g., lipoxins) (12,
43, 45–47). Resolvins, lipoxins, and aspirin-triggered SPMs exhibit
antitumor activity by promoting the clearance of therapy-generated
tumor cell debris and counterregulating proinflammatory cytokines (9, 48–51). Interestingly, unlike other synthetic nonsalicylate
NSAIDs, aspirin irreversibly acetylates COX-2 and converts its
enzymatic activity to produce aspirin-triggered SPMs. Thus, aspirin’s mechanism of action involves both inhibition of proinflammatory mediators and stimulation of proresolving mediators (12, 51).
Here, we utilize a well-established animal model in which
dormancy escape and outgrowth of lung metastases are triggered
by primary tumor resection to study therapeutic approaches to
overcoming the tumor-promoting capability of surgery. We show
that a single preoperative, but not postoperative, dose of ketorolac
suppresses lung micrometastases present at the time of primary

tumor resection, an outcome dependent on COX-2 activity and
host antitumor immunity as well as inhibition of COX-1–derived
thromboxane A2 (TXA2). Moreover, preoperative acceleration of
inflammation resolution with resolvins inhibited micrometastases
and prevented tumor-dormancy escape. Our results indicate that
preoperative and perichemotherapeutic interventions can control
tumor recurrence via inflammation resolution and promotion of
host antitumor immunity.

Results

Preoperative ketorolac eradicates micrometastases and promotes
long-term survival in multiple tumor-resection models. To investigate
whether preoperative ketorolac affects survival in tumor-resection
models, we utilized a metastatic lung cancer model in which primary syngeneic Lewis lung carcinoma (LLC) tumors were grown
to 1500–2000 mm3 in male C57BL/6J mice, resulting in micrometastases at the time of tumor resection (9, 52, 53). Following resection of primary tumors, control mice reproducibly succumbed to
lung metastasis by day 24 after resection (Figure 1A). While 60%
of mice administered preoperative ketorolac expired from macroscopic lung metastases by day 43, the remaining 40% exhibited
long-term survival (defined as >90 days after tumor resection).
In contrast, postoperative ketorolac did not prolong survival compared with that of control animals, as all postoperative ketorolac-
treated mice were moribund from spontaneous lung metastasis by
day 25 after resection (Figure 1A).
H&E staining revealed abundant micrometastases throughout
the lungs at the time of LLC resection (day 0) (Figure 1B). Micrometastases were also detected at 7 days after LLC resection in approximately 60% of ketorolac-treated mice (Supplemental Figure 1A;
supplemental material available online with this article; https://doi.
org/10.1172/JCI127282DS1). In contrast, no micrometastases were
detected in lungs from preoperative ketorolac-treated long-term
survivors (day 240) (Figure 1B). We conducted similar experiments
in the highly invasive E0771 and orthotopic 4T1 breast cancer models, which metastasize to the lungs (54). Preoperative ketorolac
resulted in long-term survival in 30% of mice at 240 days after resection compared with control mice in the E0771 model (Supplemental Figure 1B). In an orthotopic 4T1 breast cancer model in female
BALB/cJ mice, preoperative ketorolac resulted in sustained survival
in 40% of these mice after mastectomy (Supplemental Figure 1C).
Thus, the antitumor activity of preoperative ketorolac is independent of tumor type, sex, strain, or location of the primary tumor.
Ketorolac prevents surgery- and chemotherapy-induced tumor-
dormancy escape. Systemic tumor recurrence after primary tumor
resection can result from stimulation of dormant micrometastases present at the time of surgery (1, 2, 52), tumor cell dissemination during surgery (1, 55), or de novo tumorigenesis. To determine
whether ketorolac can suppress surgery- or chemotherapy-induced
tumor-dormancy escape, we utilized nonresection models in which
mice are injected with a subthreshold (nontumorigenic) inoculum
of 104 LLC, 104 EL4 (lymphoma), or 103 B16F10 (melanoma) tumor
cells. Despite the presence of tumor cells, mice in this model can
survive for over 200 days without evidence of progressive tumor
growth, thereby mimicking tumor dormancy and minimal residual disease (9, 53, 56). Consistent with surgery-stimulated tumor
growth (1–4), laparotomy performed distant from the primary
jci.org   Volume 129   Number 7   July 2019
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Figure 1. Preoperative ketorolac promotes long-term survival and prevents therapy-induced dormancy escape. (A) Preoperative vs. postoperative
ketorolac effects on survival after primary tumor resection in a spontaneous LLC metastasis model. n = 5 mice/group. Kaplan-Meier analysis log-rank test,
*P < 0.01, control or postoperative ketorolac vs. preoperative ketorolac. (B) H&E staining of lungs from mice at the time of LLC tumor resection (day 0) or
from preoperative ketorolac-treated mice at 240 days after resection. Representative micrographs of 10 mice/group. Scale bars: 50 μm. (C–E) Growth of
LLC, EL4, or B16F10 in mice treated with preoperative ketorolac or control subjected to laparotomy (day 0, 21, and/or 42 after injection) vs. no laparotomy.
n = 10–20 mice/group. Two-way repeated measure mixed-effects ANOVAs for tumor growth rates and 2-tailed Student’s t test for final tumor measurements were used throughout unless specified. (C) *P < 0.001, laparotomy vs. no laparotomy; **P < 0.001, laparotomy and ketorolac vs. laparotomy. (D)
*P = 0.009, laparotomy and ketorolac vs. laparotomy; **P < 0.001, laparotomy vs. no laparotomy. (E) *P < 0.05, laparotomy and ketorolac vs. laparotomy; **P < 0.05, laparotomy vs. no laparotomy. (F–H) Growth of LLC, EL4, or CT26 (104 cells) in response to chemotherapy and/or ketorolac. Ketorolac was
administered the day before, day of, and day after chemotherapy. Systemic chemotherapy was initiated on day of tumor cell injection. (F) n = 15–28 mice/
group. *P < 0.001, cisplatin and ketorolac vs. cisplatin (day 36 after injection). (G) n = 5 mice/group. *P < 0.05, control or vincristine and ketorolac vs.
vincristine (day 30 after injection). (H) n = 5 mice/group. *P < 0.01, control or 5-FU and ketorolac vs. 5-FU (day 25 after injection).

tumor implantation site (104 cells) stimulated LLC tumor-dormancy escape (Figure 1C). Preoperative ketorolac suppressed laparotomy-induced dormancy escape in 80% of mice by day 40 after
tumor cell injection (Figure 1C). Similarly, preoperative ketorolac
suppressed laparotomy-stimulated EL4 and B16F10 dormancy
escape in 40%–60% of mice by day 22 and day 60 after tumor cell
injection, respectively (Figure 1, D and E, and Supplemental Figure 1D). Next, we utilized GFP-labeled LLC tumor cells (104 cells)
to monitor the impact of preoperative ketorolac on dormant tumor
cells in mice subjected to laparotomy. Remarkably, LLC-GFP tumor
cells were not detected at the tumor implantation site after laparotomy in preoperative ketorolac-treated mice (Supplemental Figure
1E), suggesting that ketorolac eliminated dormant tumor cells.
2966
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While chemotherapeutic agents can suppress growth of
established tumors, they can paradoxically stimulate the growth
of a subthreshold inoculum of the identical tumor type (9, 18).
Perichemotherapeutic administration of ketorolac neutralized
chemotherapy-stimulated tumor growth in mice injected with
a subthreshold inoculum of 104 tumor cells, including cisplatin-
stimulated LLC, vincristine-stimulated EL4, and 5-fluorouracil–
stimulated (5-FU–stimulated) CT26 (colon carcinoma) (Figure 1,
F–H). However, GFP-labeled tumor cells were detected at the
tumor implantation site when ketorolac was administered with
cisplatin to mice bearing LLC-GFP tumors (Supplemental Figure
1F). Thus, ketorolac inhibited both surgery- and chemotherapy-
induced tumor-dormancy escape.
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Figure 2. COX-1 inhibition and baseline COX-2 activity are critical for the antitumor activity of ketorolac. (A) Preoperative COX-1 inhibitors (FR122047,
TFAP, or SC-560), ketorolac, or nonselective COX inhibitor (indomethacin) effects on survival after LLC resection. n = 4–6 mice/group. *P < 0.05, FR122047,
TFAP, SC-560, ketorolac, or indomethacin vs. control. (B) Preoperative NSAIDs effect on survival after LLC resection. n = 4–5 mice/group. *P = 0.003,
SC-560 vs. control; **P < 0.05, ketorolac or aspirin (10 mg/kg) vs. control. (C) Preoperative celecoxib and/or ketorolac effects on survival after LLC resection. n = 4–6 mice/group. *P < 0.05, ketorolac, celecoxib, or ketorolac and celecoxib vs. control. **P < 0.05 ketorolac or celecoxib vs. ketorolac and celecoxib. (D) Preoperative ketorolac vs. celecoxib effects on survival after LLC resection in WT or COX-2–KO mice. n = 4–9 mice/group. *P < 0.05, WT ketorolac vs.
COX-2 KO ketorolac. (E) Preoperative ketorolac and/or PGE2 depletion effects on survival after LLC resection. n = 5–6 mice/group. *P < 0.05, ketorolac, PGE2
neutralizing antibody, or ketorolac and PGE2 neutralizing antibody vs. control. **P < 0.01, ketorolac vs. ketorolac and PGE2 neutralizing antibody.

COX-1/TXA2 inhibition and basal COX-2 activity are critical
for the antitumor activity of ketorolac. Among the FDA-approved
NSAIDs, ketorolac preferentially inhibits COX-1 and exhibits
lower COX-2 activity (57, 58). To determine whether the observed
antitumor activity of preoperative ketorolac was mediated by
COX-1 and/or COX-2 inhibition, we utilized 3 highly selective
COX-1 inhibitors (SC-560, FR122047, or TFAP), the selective
COX-2 inhibitor celecoxib, and the nonselective COX inhibitor
indomethacin (38, 59). Similar to ketorolac, preoperative administration of the selective COX-1 inhibitors resulted in long-term
survival in 40%–50% of mice up to 230 days after LLC resection
(Figure 2A). However, celecoxib did not result in sustained survival (Figure 2B), suggesting that the observed antitumor activity of
ketorolac is likely mediated by COX-1 inhibition.
Although indomethacin prolonged survival compared with
control, no long-term survivors after LLC resection were noted
(Figure 2A). A similar response profile of antitumor activity was
observed with other nonselective NSAIDs, such as diclofenac,
ibuprofen, and high-dose aspirin (30 mg/kg) (Figure 2B). Aspirin
can prevent metastasis by inhibiting COX-1 activity and subsequent TXA2 synthesis (60, 61). Low-dose aspirin prolonged survival compared with high-dose aspirin (which engenders more
complete inhibition of COX-2) (Figure 2B), suggesting that preoperative COX-2 inhibition may negate the anticancer activity of
ketorolac. Indeed, preoperative coadministration of celecoxib and

ketorolac resulted in no long-term survivors (Figure 2C). To confirm that COX-2 inhibition may impair the activity of preoperative
ketorolac, we next performed the LLC tumor-resection experiments in COX-2–KO mice. While preoperative ketorolac resulted
in long-term survival after resection in WT mice, long-term survival was not observed in COX-2–KO mice (Figure 2D). Moreover, the
combination of preoperative ketorolac and an anti-PGE2 neutralizing antibody did not result in any long-term survivors after resection (Figure 2E). Therefore, in the LLC tumor-resection model,
baseline COX-2 activity and PGE2 levels may be necessary for the
antitumor activity of ketorolac.
Since COX-1 preferentially mediates TXA2 production (38,
61), we measured plasma TXB2, a stable hydration product of
TXA2 used to assess COX-1 activity. Profiling based on liquid chromatography–tandem mass spectrometry (LC-MS/MS) revealed
dramatic reduction of TXB2 at 2 hours after LLC resection as well
as a lesser reduction in PGE2 in ketorolac-treated mice compared
with control (Figure 3, A and B). To ascertain a functional role
for TXA2 in the observed antitumor activity of ketorolac, we performed primary tumor resections in mice lacking the thromboxane prostanoid (TP) receptor. TP-KO mice exhibited long-term
survival compared with WT mice (Figure 3C). Moreover, preoperative administration of the highly specific, high-affinity TP-TXA2
antagonist terutroban also resulted in prolonged survival after
LLC resection in 40% of mice (Figure 3D). Conversely, the TP
jci.org   Volume 129   Number 7   July 2019
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Figure 3. COX-1/TXA2 inhibition mediates the antitumor activity of ketorolac. LC-MS/MS–based analysis of (A) TXB2 or (B) PGE2 in plasma 2 hours after
LLC resection from control or preoperative ketorolac-treated mice. n = 5 mice/group. *P < 0.05 vs. control. (C) Survival of TP KO mice vs. WT mice after LLC
resection. n = 5 mice/group. *P = 0.002, WT vs. TP KO mice. (D) Preoperative clopidogrel, terutroban, U-46619, and/or ketorolac effects on survival after
LLC resection. n = 4–5 mice/group. *P < 0.01, ketorolac, terutroban or clopidogrel vs. control. **P = 0.005 U-46619 vs. ketorolac. H&E staining of lungs
from preoperative (E) terutroban-, or (F) clopidogrel-treated mice at 180 days after LLC resection. Scale bars: 50 μm.

receptor agonist U-46619 accelerated morbidity from lung metastasis compared with control and abrogated the antitumor activity
of ketorolac (Figure 3D). Since TXA2 stimulates platelet aggregation (38, 61), we also evaluated the activity of the antiplatelet
agent clopidogrel. Preoperative clopidogrel prolonged survival
after LLC resection compared with control, resulting in 20% longterm survivors (Figure 3D). Similarly to preoperative ketorolac, no
micrometastases were detected in the lungs of long-term survivors
administered preoperative terutroban or clopidogrel on day 180
after LLC resection (Figure 3, E and F). Selective COX-2 inhibitors
do not affect platelet TXA2 production and may not directly impair
platelet aggregation (38, 60). Collectively, these results suggest
that the antitumor activity of ketorolac is in part driven by COX-1/
TXA2 inhibition and subsequent reduction in platelet aggregation
and accompanying degranulation.
Preoperative resolvins eradicate micrometastases and inhibit
tumor-dormancy escape. LC-MS/MS analysis of plasma from preoperative ketorolac-treated mice after LLC resection demonstrated a
global shift in the lipid-mediator profile (Supplemental Figure 2).
Not only were COX-dependent and nonenzymatic oxidation products affected, but there was also shunting of the arachidonic acid
cascade to the lipoxygenase (LOX) and cytochrome P450 (CYP)
pathways. Specifically, ketorolac increased LOX-derived 12-oxoETE and 13-HODE as well as the tumorigenic CYP450-derived
5,6-EET, 11,12-EET, and 10,11-EDP compared with control (Sup2968

jci.org   Volume 129   Number 7   July 2019

plemental Figure 2). This broad lipidomic shift indicates a complex
balance between pro- and antitumorigenic mediators (53), which
may account for the observed subset of ketorolac-treated mice that
developed invasive lung metastasis (Figure 1A). Notably, lipoxin
A4 (LXA4) was increased in the plasma of preoperative ketorolac-
treated mice after LLC resection (Figure 4A). Since LXA4 is an SPM
(12), we reasoned that the balance of inflammation regulation may
be tipped toward resolution, thereby either enhancing or recapitulating the antiinflammatory and proresolving activity of ketorolac.
Indeed, SPMs, such as lipoxins and resolvins, possess potent antitumor activity in experimental models (9, 48–51, 62).
To determine whether stimulation of inflammation resolution
could prevent tumor recurrence and/or suppress outgrowth of
micrometastases, we administered resolvins via osmotic pump 2
hours prior to tumor resection. Preoperative resolvin D2 (RvD2)
prolonged survival after tumor resection and was more potent
in preventing metastasis than RvD2 administered at the time of
surgery (Figure 4B). Specifically, preoperative administration of
resolvins (RvD2, RvD3, or RvD4) resulted in 50%–80% survival
at 37 days after resection, with RvD2 exhibiting the most potent
antitumor activity (Figure 4C).
Since low-dose aspirin triggers the production of resolvins from
omega-3 fatty acids (12), we treated mice with low-dose aspirin in
combination with an omega-3 fatty acid diet and found increased
survival, but no long-term survivors (Figure 4D). Although aspirin

The Journal of Clinical Investigation  
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Figure 4. Preoperative resolvins eliminate micrometastases and prevent surgery-stimulated dormancy escape. (A) LC-MS/MS–based analysis of LXA4 in
plasma 2 hours after LLC resection from control or preoperative ketorolac-treated mice. n = 5 mice/group. *P < 0.05 vs. control. (B) Preoperative vs. perioperative RvD2 effects on survival after LLC resection. n = 5 mice/group. *P < 0.05, preoperative RvD2 vs. perioperative RvD2. (C) Preoperative resolvins
effects on survival after LLC resection. n = 5 mice/group. *P < 0.05, RvD2 or RvD3 vs. control. (D and E) Preoperative omega-3 or omega-6 fatty acid
diet and/or low-dose aspirin (10 mg/kg/d) effects on survival after LLC resection. Diet and aspirin were administered 7 days before and 3 days after LLC
resection and preoperative ketorolac. n = 5 mice/group. *P < 0.05 vs. omega-6 fatty acid diet. H&E staining of lungs from mice treated with preoperative
(F) RvD2 or (G) ketorolac, low-dose aspirin, and omega-3 fatty acid diet on day 180 after LLC resection. n = 4–5 mice/group. Scale bars: 50 μm. (H) Growth
of EL4 (104 cells) after preoperative RvD2 and laparotomy. n = 5–10 mice/group. *P < 0.05, laparotomy vs. no laparotomy; **P < 0.05, laparotomy and RvD2
vs. laparotomy.

or omega-3 fatty acid diet alone exhibited less antitumor activity
than the combination treatment, survival was prolonged compared
with that of mice fed an omega-6 fatty acid diet. The omega-6 fatty acid diet alone accelerated progression and shortened median
survival in mice from 19 days (control, Figure 2, A and B) to 16 days
(Figure 4E) after resection, consistent with studies suggesting that
dietary omega-6 fatty acids can promote tumor progression and
metastasis (53). Moreover, the omega-6 fatty acid diet alone markedly shortened survival compared with combinations with aspirin,
RvD2, and/or ketorolac (Figure 4E).
The potent antitumor activity of low-dose aspirin combined
with omega-3 fatty acids offered the opportunity to examine whether promotion of resolution of inflammation could synergize with the

antiinflammatory activity of ketorolac. Intriguingly, preoperative
ketorolac in combination with low-dose aspirin and omega-3 fatty
acid diet resulted in 90% survival at 110 days after resection (Figure
4D). The combination of preoperative ketorolac and resolvins led to
long-term survival after resection in 70% of mice administered the
omega-6 fatty acid diet (Figure 4E). Tumor cells were undetectable
in H&E-stained sections of lungs from long-term survivors treated
with preoperative RvD2 or the combination of low-dose aspirin,
omega-3 fatty acids, and ketorolac (day 180) (Figure 4, F and G).
To determine whether the antitumor activity of resolvins
extended to a surgery-induced tumor-dormancy escape model,
we injected 104 EL4 into mice and performed a laparotomy, which
triggered dramatic tumor outgrowth. Preoperative RvD2 preventjci.org   Volume 129   Number 7   July 2019
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Figure 5. Ketorolac restores antitumor immunity. (A) Preoperative ketorolac effects on survival of SCID or C57BL/6J mice after LLC resection. n = 5–10
mice/group. *P = 0.04, C57BL/6J ketorolac vs. C57BL/6J control; **P = 0.004, SCID control vs. C57BL/6J control (day 14 after resection). (B) Growth of EL4
(104 cells) after preoperative ketorolac and/or laparotomy in SCID and C57BL/6J mice. Laparotomy was performed on day 0. n = 5–10 mice/group. *P <
0.05, C57BL/6J (laparotomy and ketorolac) vs. C57BL/6J (laparotomy). (C) Percentage of control or preoperative ketorolac-treated C57BL/6 or RAG1-KO
mice demonstrating LLC tumor-dormancy escape. Laparotomies were performed on days 0, 21, and 42 after injection. n = 5–10 mice/group. *P < 0.05, WT
(laparotomy and ketorolac) vs. WT (laparotomy). (D) Preoperative ketorolac effects on survival of athymic mice after LLC resection. n = 3–4 mice/group.
(E) Preoperative ketorolac and T cell depletion effects on survival after LLC resection. T cell–depleting (CD4+ or CD8+) antibodies or control (rat IgG2b) were
administered 3 days before tumor resection, the day of tumor resection, and every 3 days thereafter for 2 weeks. n = 5 mice/group. *P < 0.05, control
(IgG); CD4+ and CD8+ depletion and ketorolac; CD4+ depletion and ketorolac or CD8+ depletion and ketorolac vs. ketorolac. (F) Expression of FOXP3, CD4,
and CD8 (brown DAB staining) in spleens from preoperative ketorolac-treated vs. control mice on day 5 after LLC resection. Scale bar: 100 μm. Immune cell
quantification is represented as mean ± SEM. n = 4–5 mice/group. *P < 0.05 vs. control.

ed surgery-induced EL4 tumor-dormancy escape (Figure 4H).
Thus, preoperative stimulation of inflammation resolution with
resolvins may inhibit surgery-induced tumor recurrence.
The antitumor activity of ketorolac is T cell dependent and impaired
by chemotherapy. Inflammation plays a multifaceted role in regulating
the adaptive immune response. For example, prostaglandins, such
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as PGE2, suppress acute inflammatory mediators, activate dendritic cells, sensitize T cells to eliminate infection, and promote T cell
exhaustion (36, 42). Moreover, adaptive antitumor immunity has
been implicated in the regulation of metastatic tumor dormancy (63,
64). These facts, along with the absence of tumor cells in the lungs of
long-term survivors, led us to examine whether the immune system
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Figure 6. Antitumor activity of ketorolac is mediated by T cell immunity. (A and B) Preoperative ketorolac and immune checkpoint blockade (anti–PD-1)
on survival after tumor resection (LLC or EL4). Anti–PD-1 (200 μg/mouse q 3 days for 60 days). n = 5–10 mice/group. (A) *P = 0.002, ketorolac and anti–
PD-1 vs. control (IgG) or anti–PD-1 alone. (B) *P < 0.05, control (IgG), ketorolac and control (IgG), or anti–PD-1 vs. ketorolac and anti–PD-1. (C) Preoperative
ketorolac and/or anti–PD-1 (1 dose, 200 μg/mouse) effects on spontaneous LLC lung metastasis at 24 days after LLC resection. n = 4 mice/group. Images
show representative lung metastasis in preoperative ketorolac and/or anti–PD-1, and control mice. Scale bar: 1 cm. Bar graph is presented as lung weight
(g) ± SEM per group. *P = 0.002, ketorolac vs. control; **P < 0.001, ketorolac and anti–PD-1 vs. anti–PD-1. (D) Preoperative ketorolac-treated C57BL/6J
mice that survived 90 days after LLC resection were injected with 106 LLC and compared with naive control mice. Ninety days later, ketorolac-treated mice
were rechallenged with 106 B16F10. *P < 0.05, ketorolac vs. control. LLC tumor growth (106 cells) after adoptive cell transfer of (E) splenocytes or (F) isolated
CD8+ T cells from preoperative ketorolac-treated long-term survivors (90 days) after LLC resection or naive control mice. n = 3–5 mice/group. (E and F)
*P < 0.05, ketorolac vs. control.

plays a role in the antitumor activity of ketorolac. Preoperative ketorolac prolonged survival in 60% of immunocompetent C57BL/6J mice
up to 120 days after LLC resection (Figure 5A). In contrast, ketorolac did not improve survival after resection in SCID mice, which lack
functional B and T lymphocytes (Figure 5A). SCID mice exhibited a
drastically shortened baseline survival in the LLC tumor-resection
model, with a median overall survival of 10 days compared with 25
days in C57BL/6J mice (Figure 5A). Similarly, ketorolac did not affect
laparotomy-induced tumor-dormancy escape in immunodeficient
SCID or RAG1-KO mice (Figure 5, B and C).
To investigate the specific role of T cells in the antitumor
activity of ketorolac, we utilized nude athymic mice in a C57BL/6J
background. The antitumor activity of ketorolac was abrogated in
these mice, as all of the ketorolac-treated mice succumbed to lung
metastasis by day 22 after LLC resection (Figure 5D). To confirm
that the observed antitumor activity of ketorolac was T cell mediated, we depleted CD8+ and/or CD4+ T cells in vivo using neutralizing antibodies. T cell depletion of either subtype abolished the
antitumor activity of ketorolac (Figure 5E), confirming that both

T cell subtypes are necessary for the ketorolac-induced antitumor
response. Immunohistochemistry revealed increased CD8+ and
CD4+ T lymphocytes and decreased cells positive for the regulatory T cell marker FOXP3 in the spleen and lung tissues of ketorolac-treated mice on days 5 and 7 after resection, respectively, as
compared with control mice (Figure 5F and Supplemental Figure
3A). RvD2 also increased CD8+ T lymphocytes in the lung tissues of mice (day 180 after resection) (Supplemental Figure 3B).
Therefore, the antitumor activity of ketorolac and resolvins may
be mediated by activation of CD4+ and/or CD8+ T cells.
Since checkpoint inhibitors such as anti-programmed cell
death protein 1 (anti-PD1) antibody can augment cytolytic T
cell responses, we hypothesized that preoperative ketorolac and
immune-checkpoint blockade may act synergistically in our
resection models. Indeed, this combination resulted in synergistic
antitumor activity, with approximately 80% of animals exhibiting
long-term survival in both syngeneic LLC and EL4 tumor-resection models (Figure 6, A and B). While ketorolac alone exhibited
antitumor activity that was further enhanced by anti-PD1 treatjci.org   Volume 129   Number 7   July 2019
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Figure 7. ScRNA-Seq analysis demonstrates an altered immune landscape in response to ketorolac. ScRNA-Seq analysis on splenic cells isolated from
preoperative ketorolac-treated or control mice 7 days after LLC resection. n = 2 mice/group throughout. (A) 2D visualization of single-cell clusters generated
using the tSNE approach from normalized data of 2429 ketorolac-treated and 1864 control splenic cells. Cell clusters were annotated based on expression of
established immune cell markers, e.g., T cells (Cd3d+), exhausted T cells (Pdcd1, Ctla4, Lag3, Entpd1, and TIM3), T memory cells (Il7r, Ccr7, Sell, CD44), B cells
(Cd19+), dendritic cells (Itgax), and macrophages (Adgre1) (left panel). Chart depicts relative proportions of cells in the clusters from each sample (right panel).
(B) Percentage of cells from control and ketorolac-treated mice, per cluster. (C) Preoperative ketorolac effects on the immune landscape of T cells. Feature
maps depict the expression of T cell (Cd3d+), exhausted T cell (Pdcd1), and memory T cell (Il7r) markers for each cell cluster on the tSNE map. Cells from ketorolac-treated and control samples are shown as solid dots and triangles, respectively. Bar plots depict the relative proportions of T cell subpopulations in control
and ketorolac-treated single-cell profiles. (D) Heatmap depicts the activation or inhibition of key regulators in the control and ketorolac-treated T cell clusters.
Regulators were calculated based on Z scores using an upstream regulator analysis module in ingenuity pathways analysis systems.

ment, anti-PD1 alone did not exhibit antitumor activity in these
models (Figure 6, A–C). Moreover, preoperative ketorolac alone or
in combination with anti-PD1 suppressed lung metastasis on day
24 after LLC resection (Figure 6C).
To corroborate the antitumor immunity stimulated by ketorolac,
we assessed immunological memory by rechallenging long-term
survivors administered ketorolac prior to tumor resection with the
identical tumor type (106 LLC cells). These long-term survivors were
resistant to LLC rechallenge, as no visible tumors were observed over
2972
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100 days after injection. When these mice were injected with a second syngeneic tumor type (106 B16F10), they exhibited rapid tumor
growth (Figure 6D), suggesting tumor-specific immunity. Similarly,
preoperative ketorolac-treated long-term survivors in the postlaparotomy and postchemotherapy LLC tumor-dormancy escape models
were resistant to LLC challenge, but exhibited rapid tumor growth
when challenged with B16F10 tumor cells (Supplemental Figure 4,
A and B). Moreover, preoperative RvD2-treated long-term survivors
after LLC resection were also resistant to LLC rechallenge for over
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Figure 8. Key regulators in granulocytes/neutrophils from preoperative ketorolac-treated and control mice. Spleens from preoperative
ketorolac-treated and control mice are identical to those used in Figure
7. (A) Feature and bar plots highlight the proportion of Ly6g +- and
Mmp9-producing granulocytes/neutrophils in spleens from ketorolac-treated or control mice. (B) Interactive network of key regulators
significantly activated in granulocytes/neutrophils from control mice.
Bar graph depicts Z score (>1.5 = activation, < 1.5 = inhibition) of NF-κB
and PI3K complexes in control and ketorolac-treated samples based on
expression of genes in the granulocyte/neutrophil cluster.

90 days after injection, yet developed aggressive tumor growth when
injected with B16F10 (Supplemental Figure 4C). To confirm that
the antitumor activity of ketorolac may be mediated by CD8+ T cell
activation, we performed adoptive transfer of immune cells from preoperative ketorolac-treated long-term survivors after LLC resection
into naive mice. Splenocyte or CD8+ T cell transfer from long-term
ketorolac-treated survivors inhibited LLC growth compared with that
of control mice that received splenocytes or CD8+ T cells from naive
mice (Figure 6, E and F, and Supplemental Figure 5, A–D).
Cancer patients undergoing tumor resection often receive
adjuvant chemotherapy, as perioperative chemotherapy may be
most effective when administered before surgery, at the time of
surgery or soon after surgery (65, 66). Thus, we determined whether administration of chemotherapy after preoperative ketorolac
would affect survival and antitumor immunity after tumor resection. A single dose of cisplatin on day 7 after LLC resection abrogated the long-term survival observed in the preoperative ketorolac
group (Supplemental Figure 6A). Immunohistochemistry revealed
that chemotherapy following preoperative ketorolac reduced the
number of CD4+ and CD8+ T cells compared with preoperative
ketorolac alone on day 7 after LLC resection (Supplemental Figure 6B). Adjuvant chemotherapy is typically administered 4 to 6
weeks after surgery. We therefore asked whether delayed adminis-

tration of chemotherapy would also influence preoperative ketorolac-treated long-term survivors. Ketorolac-treated mice surviving
over 90 days after LLC resection were subjected to 3 cycles of cisplatin (5 mg/kg q 5 days) and then rechallenged with LLC tumor
cells. This challenge resulted in a rapid onset of LLC tumor growth
in the ketorolac-treated as well as control mice (Supplemental Figure 6C). Therefore, adjuvant chemotherapy, even when administered a few weeks after tumor resection, may interfere with the
antitumor immunity of preoperative ketorolac.
Single-cell profiling of immune cell populations in response to
ketorolac. To characterize the ketorolac-mediated immunomodulatory response, we utilized droplet-based single-cell RNA-Seq
(scRNA-Seq) to obtain single-cell resolution transcriptomes of
splenic tissues from control and ketorolac-treated mice on day 7
after LLC resection. The transcriptome profiles of 1864 and 2429
individual cells from spleens of 2 control and 2 ketorolac-treated
mice, respectively, revealed that ketorolac modulated the immune
landscape by altering the relative abundance and transcriptome
profiles of T cells and granulocytes. Standard cluster analysis of
cells based on their most variably expressed genes in the scRNASeq transcriptomes is shown in the projection of gene expression
space onto a single 2D space using t-distributed stochastic neighbor embedding (tSNE) (Figure 7A). The 2D plot contains cells
jci.org   Volume 129   Number 7   July 2019
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from both ketorolac-treated and control samples analyzed as 1
concatenated data set. Analysis of marker genes assigned the 17
identified robust clusters to T cells, B cells, erythroid cells, NK
cells, granulocytes, neutrophils, macrophages, and dendritic cells
(Figure 7A). Only 1 cell cluster was mouse specific and unrelated to
treatment, while the majority of clusters were formed by all mice
and represent known cell types — indicating minimal batch or
mouse effect (Figure 7A). Ketorolac-treated spleens differed from
control in relative cell-type abundance and gene expression states
of individual cells.
At the level of cell-type abundance, with the exception of
a few clusters that contained only or predominantly cells from
control samples, the clusters contained varying proportions from
both control and ketorolac-treated mice (Figure 7B). In both mice,
ketorolac increased the fraction of splenic Cd3d+ T cells compared
with those of control, from 9.12% to 19.1% (clusters 1 and 13 in Figure 7A). One T cell cluster (cluster 13 in Figure 7A) was enriched
in exhausted T cells (as determined by expression of markers
PD1, CTLA4, and TIM3) from 1 control mouse, while both ketorolac-treated mice had low numbers of exhausted T cells (Figure 7, B
and C). Moreover, the proportion of memory T cells (IL7r+) (cluster 1 in Figure 7A) increased from 32% in the 2 control spleens to
52% in the 2 ketorolac-treated spleens (Figure 7C). Although T
cell–subtype abundance varies considerably between individuals
(67), this finding is consistent with systemic activation of T cell
immunity in the ketorolac-treated mice. This constellation suggests that ketorolac may improve T cell antitumor immunity and
the presence of exhausted PD1+ T cells is consistent with ketorolac’s synergism with an anti-PD1 inhibitor (Figure 6, A and B).
At the transcriptome level within the T cell clusters, shifts
in cell phenotypic states of control and ketorolac-treated mice
(enrichment of cells from 1 mouse in a subregion of a cluster,
Figure 7A) are apparent in the tSNE plots. Utilizing a systematic
quantitative analysis, we focused on T cells and identified genes
that were significantly enriched in each cluster (P < 0.01) and then
performed a pathway analysis on these genes for the control and
ketorolac-treated mice independently. Such gene ontology analysis suggested that distinct upstream regulators are significantly
activated or inhibited in the different T cell clusters from control
and ketorolac-treated mice (Figure 7D). The upstream regulator
analysis (68) on genes associated with the exhausted T cell cluster in the control spleens indicated states controlled by transcription factor GATA3 and the cytokine VEGFA, which are associated
with angiogenesis and Th2 polarization (69). In contrast, the same
analysis in spleen cells from ketorolac-treated mice suggested activation of a state under control of the transcription factor 7 (TCF7)
and the cytokines TNF-α, IFN-γ, and IFN-α (Figure 7D), which are
associated with activated cytotoxic T cells. Of note, TCF7, which is
associated with memory T cells and implicated in rescuing T cells
from exhaustion by anti–PD-1 therapy (70), was activated in the
CD8+ T cells of ketorolac-treated mice.
In addition, scRNA-Seq analysis demonstrated reduced Ly6g+
granulocytes in spleens of both ketorolac-treated mice (35 out of
2429 cells, 1.4%) as compared with the control mice (65 out of 1864
cells, 3.5%) (Figure 8A, cluster 12 in Figure 7A). A significant global shift in gene expression profiles of granulocytes from ketorolac-
treated versus control mice was not observed. However, the pro2974
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portion of Mmp9-expressing Ly6g+ cells was significantly higher in
the spleens of control compared with ketorolac-treated mice (Figure 8A). MMP9 is a critical protein that promotes the expansion of
Ly6g+ myeloid-derived suppressor cells (71). Moreover, upstream
regulator analysis (68) of the granulocyte cluster indicated that
NF-κB and PI3K were significantly activated in granulocytes from
control mice compared with ketorolac-treated mice (Figure 8B),
which is consistent with the suppressive activity of NSAIDs (72).
The pathways and functions enrichment analysis also depicted
alterations in triacylglycerol, carbohydrate, and lipid metabolism in
ketorolac-treated granulocytes (Supplemental Table 1). We speculate that the low PI3K activity in the ketorolac-treated samples may
decrease glycolysis (73), the major pathway of energy generation for
granulocytes (74), and diminish migration (75).

Discussion

Here, we demonstrate that preoperative, but not postoperative,
ketorolac and/or resolvins eradicate micrometastases in multiple tumor-resection models. While we cannot exclude minimal
residual disease due to individual disseminated malignant cells,
the elimination of metastatic recurrence by preoperative ketorolac
resulted in long-term survival after tumor resection. These interventions also prevented dormancy escape induced by surgery or
chemotherapy in several tumor types. The antitumor activity of
ketorolac is dependent on a T cell–mediated response, as its activity was enhanced by immune checkpoint blockade and abrogated in athymic mice. Consistent with the immunohistochemistry,
single-
cell transcriptomics demonstrated increased CD4+ and
+
CD8 T cells in the spleens of ketorolac-treated mice as well as a
shift in the proportions of T cell subtypes, indicating an increase
in memory T cells and reduction of exhausted T cells. The T cell
response may be specific for tumor cells, since ketorolac-treated
mice were protected against a secondary challenge with the same
tumor type, but not from an unrelated type. Moreover, adoptive
transfer confirmed that the protective antitumor activity of ketorolac was T cell mediated, as no tumor growth was observed in mice
that received T cells from ketorolac-treated long-term survivors.
Therefore, targeting cancer therapy–induced inflammation with
preoperative ketorolac and/or resolvins may reduce tumor recurrence and metastatic outgrowth via a T cell response.
Our study provides insight into the multifaceted roles of
cyclooxygenase enzymes and their products in tumor biology.
Specifically, we establish the importance of inhibiting COX-1
while maintaining COX-2 activity to control tumor recurrence
or metastasis. These results shed light on the conceptual framework of inflammation and adaptive immunity in cancer. For
instance, COX inhibition is generally thought to contribute to
the prevention and control of tumor growth (38, 76). In the context of surgery, the NSAID meloxicam was recently reported to
suppress dormancy escape of micrometastatic lesions in mouse
models (2). However, we show that COX-2 inhibition may hinder
the antitumor activity of ketorolac via impairment of the resolution of inflammation. In fact, selective COX-2 inhibitors have not
improved recurrence-free survival in the clinic (77–81). Rather,
chronic COX-2 inhibition or NSAIDs (e.g., sulindac) are linked to
increased risk of breast and hematological cancers and can result
in resistant adenomas and breakthrough carcinomas (82, 83).
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Moreover, while a combination of COX-2 inhibitors with adjuvant temozolomide following resection of glioblastoma extended progression-free survival, the COX-2 inhibitors also increased
the rate of metastasis (84).
In addition, COX-2–derived PGE2 exhibits complex and
opposing activities. PGE2 has been implicated in the suppression
of antitumor immunity (85–87), as it can hinder antigen presentation, inhibit T cell and NK cell effector functions, and promote
the activity of regulatory T cells (36, 85, 88). In contrast, PGE2 may
be necessary for optimal CD8+ T cell response (38, 89), supporting our finding that baseline COX-2 is critical for the antitumor
immune response of ketorolac. PGE2 also plays a critical role in
the termination of inflammation, as it is required for a bioactive
lipid-class switching to generate SPMs that promote the resolution of inflammation (40). The proresolution activities of PGE2 on
both the innate and adaptive immune system (12) may explain why
selective COX-2 inhibition with celecoxib impaired the antitumor
activity of preoperative ketorolac (Figure 2C).
The importance of COX-1 inhibition in cancer is poorly characterized and has not been translated to cancer patients (38). TXA2
synthesis is independent of COX-2 (90), which is consistent with
our finding that the antitumor activity of preoperative ketorolac
is mediated by COX-1/TXA2 inhibition. In addition, 20% of mice
treated preoperatively with the antiplatelet agent clopidogrel
demonstrated long-term survival in our tumor-resection model,
consistent with reports showing that clopidogrel prevents carcinogenesis by restoring antitumor immunity, including increasing the
number of tissue CD8+ T cells (91). Clopidogrel also stimulates
CD4+ and CD25+ T cells in an atherosclerosis model (92). Studies suggest a direct role for TXA2 in dendritic cell maturation and
neutrophil migration (90), which may account for our genetic and
pharmacologic data on the role of the TXA2 receptor in reducing
postresection tumor recurrence.
Our findings have important therapeutic implications. First,
ketorolac may increase long-term survival in multiple cancer
types if administered preoperatively, rather than postoperatively,
per current standards of care. Second, while ketorolac is a simple,
inexpensive, and relatively nontoxic treatment, potential concerns include the risk of bleeding, wound dehiscence, and acute
kidney injury. These side effects were not noted in a human retrospective study (34). In contrast, SPMs dampen inflammatory
mediator release from platelets and do not appear to increase the
risk of bleeding nor to enhance the hemostatic function of platelets (12, 93). In our animal studies, ketorolac and resolvins demonstrated synergistic antitumor activity without overt toxicity. Third,
our results suggest that coadministration of preoperative ketorolac
and immune checkpoint inhibitors may provide optimal therapeutic efficacy, consistent with recent studies (2, 24, 25). High-risk
stage III melanoma may be an ideal setting to assess the potential
therapeutic benefit of combining ketorolac and checkpoint inhibitors, as checkpoint inhibitors alone have been shown to decrease
risk of recurrence (94). Fourth, although adjuvant chemotherapy
increases overall survival in select cancer patients, it may also harbor inherent tumor-promoting activity (9, 10, 18, 95–97) limiting
its overall efficacy, including inflammation-associated impairment of antitumor immunity that could stimulate micrometastatic
disease. Indeed, administration of chemotherapy within 7 days of
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surgery was detrimental to achieving effective antitumor T cell
immunity, which may be due to cytotoxicity on proliferating T
cells. Even when administered several weeks after resection, chemotherapy appears to abrogate T cell memory and may increase
the likelihood of recurrence. Fifth, dormant tumor cells are typically resistant to adjuvant chemotherapy (98), and chemotherapy can awaken dormant micrometastases. Although we did
not specifically study the combination of resolvins and ketorolac with chemotherapy, tumor-dormancy escape was inhibited
in a subset of mice when ketorolac was administered alongside
chemotherapy (Figure 1, F–H). We also found via LC-MS/MS–
based profiling that ketorolac stimulated an increase in plasma
LXA4. Moreover, systemic treatment with resolvins inhibits chemotherapy-stimulated tumor growth in multiple tumor models
(9). Collectively, our data suggest that flanking chemotherapy with antiinflammatory or proresolution therapies may be a
novel approach for cancer treatment. Sixth, cancer patients in
remission may benefit from preoperative ketorolac or resolvins
prior to surgery, since surgery or even biopsy can induce tumor-
dormancy escape or metastasis (1, 6, 8). The relapse pattern following delayed reconstructive surgery in breast cancer patients
is bimodal, suggesting a systemic action on dormant micro
metastases from surgery (30). Seventh, although it may be
tempting to enroll patients at highest risk for recurrence in trials
of ketorolac or resolvins, these patients are likely to receive neoadjuvant or adjuvant chemotherapy, radiation (encompassing
draining lymph nodes), and/or have their draining lymph nodes
resected per current clinical guidelines. These interventions may
counteract the induction of an effective T cell immune response.
It may therefore be prudent to first conduct small biomarker
endpoint studies to assess the impact of preoperative ketorolac
and/or resolvins on T cell response via monitoring activation of
CD8+ cells after surgery, T cell response to predicted neoantigens, T cell receptor diversity, or single-cell sequencing. Thus, if
neoadjuvant chemotherapy negates an antitumor T cell response
despite administration of preoperative ketorolac, such patients
would then be excluded from a randomized prospective study.
Collectively, our data suggest a paradigm shift in clinical
approaches to resectable cancers. Over the last century, the
field has evolved from a “more is better” Halstedian stance with
increasingly radical surgeries to a view of early stage cancer as a
systemic disease, resulting in the adoption of adjuvant and neoadjuvant chemotherapy. Now, we and others (2) are showing that
it may be possible to eradicate micrometastatic disease and dormant tumor cells without chemotherapy. Here, we demonstrate
that unleashing T cell immunity by preoperative suppression
of systemic inflammation or stimulation of inflammation resolution exhibits potent antitumor activity, even curing mice of
micrometastases. Pharmacological enhancement of resolution
via exogenous resolvins (demonstrated here with RvD2, RvD3,
and RvD4) at ng/d doses or omega-3 fatty acid supplementation
restores endogenous SPMs. Moreover, ketorolac and resolvins
demonstrate synergistic antitumor activity. Thus, simultaneously
blocking proinflammatory responses with ketorolac and activating endogenous resolution programs via resolvins may represent a
novel approach for preventing systemic recurrence in the context
of locoregional disease.
jci.org   Volume 129   Number 7   July 2019
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Methods

Tumor resection. Tumors were resected at 1500–2000 mm3. 106 LLC
cells (ATCC) were subcutaneously injected into male C57BL/6J, SCID,
athymic C57BL/6J, TP KO, WT, or COX-2–KO mice (Jackson Laboratory). Experiments were repeated 3 times with similar results. For
orthotopic tumors, 5 × 104 4T1 (ATCC) or E0771 (CH3 BioSystems)
were injected into the fourth mammary fat pad of female BALB/cJ or
C57BL/6J mice, respectively.
Drug administration. Drugs were administered preoperatively (2
hours before surgery), at the time of surgery, or postoperatively (2
hours after surgery). For chemotherapy, mice were treated with preoperative ketorolac (7.5 mg/kg) and a postoperative dose of cisplatin
(5 mg/kg) on day 7 after tumor resection. For immune-checkpoint
blockade, mice were treated preoperatively with anti-mouse PD-1
(CD279; clone RMP1-14) (200 μg/mouse; Bio X Cell). For COX inhibition, mice were treated preoperatively with FR122047 (20 mg/
kg), TFAP (30 mg/kg), SC-560 (30 mg/kg), celecoxib (60 mg/kg),
indomethacin (3 mg/kg), ibuprofen (30 mg/kg), diclofenac (10 mg/
kg), or aspirin (10 or 30 mg/kg). For TXA2 inhibition, mice were
treated preoperatively with terutroban (30 mg/kg), U-46619 (2 μg/
kg), or clopidogrel (10 mg/kg). For T cell depletion, anti-mouse CD4
(clone GK1.5), anti-mouse CD8 (clone 53-6.72), or isotype control
(rat IgG2b) obtained from Bio X Cell was utilized (200 μg/mouse q
3 days, i.p.). For PGE2 studies, mice were treated preoperatively with
ketorolac and a PGE2-neutralizing antibody (Cayman Chemical)
(200 μg/mouse q 3 days) or isotype control (rat IgG2b). Resolvins
(RvD2, RvD3, or RvD4) (15 ng/d/mouse) were administered via
miniosmotic pump (Alzet Inc.) 2 hours prior to tumor resection
or laparotomy. Meloxicam SR was administered after surgery per
IACUC-approved protocol.
Laparotomy. C57BL/6J or RAG1-KO male mice (Jackson Laboratory) were injected with 104 LLC, 103 B16F10, or 104 EL4 cells and subjected to laparotomy under isoflurane inhalation anesthesia. Bowels
were removed, placed on a sterile sheet for 4 minutes, and returned
to the peritoneum. The skin was sutured with 4-0 chromic gut absorbable sutures. Tumor size was measured by caliper (width2 × length ×
0.52 = mm3).
Chemotherapy-stimulated cancer. For dormancy models, 104 LLC,
EL4, or CT26 cells (ATCC) were subcutaneously injected into male
C57BL/6J (LLC and EL4) or BALB/cJ (CT26) mice. Cisplatin (5 mg/kg
q 5 days), vincristine (1 mg/kg q 7 days), or 5-FU treatment (30 mg/kg
q 3 days) was initiated on the day of tumor cell injection. For combination therapies, ketorolac (7.5 mg/kg) was administered the day before,
day of, and day after cisplatin or vincristine as well as the day before
and day of 5-FU treatment.
Tumor rechallenge. Preoperative ketorolac- or RvD2-treated mice
that survived 90 days after LLC resection and naive age-matched
mice were challenged with 106 LLC via subcutaneous injection. On
day 90 after LLC rechallenge, the LLC tumor-resected mice treated
with preoperative ketorolac or RvD2, which did not grow tumors, were
subcutaneously injected with 106 B16F10.
Preoperative ketorolac-treated LLC tumor-bearing mice (104
cells) were subjected to a laparotomy. Ninety days after laparotomy,
these mice and naive age-matched mice were challenged with 106 LLC
via subcutaneous injection. On day 90 after LLC rechallenge, the preoperative ketorolac-treated mice subjected to laparotomy, which did
not grow tumors, were subcutaneously injected with 106 B16F10.
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Adoptive transfer. Splenocytes were obtained as follows: spleens
from preoperative ketorolac-treated mice after LLC resection or agematched naive C57BL/6J mice were dissociated and filtered through
40 μm strainers. CD8α+ T cells were isolated from this population by
magnetic selection using a mouse CD8α+ T Cell Isolation Kit (Miltenyi
Biotec). Splenocytes or isolated CD8α+ T cells were stained with CD8α
APC-conjugated antibody (clone 53-6.7; R&D systems) and CD3
FITC-conjugated antibody (clone 17A2; BioLegend). Staining was
assessed via BD LSR Fortessa (BD Biosciences) at the DFCI Cytometry Core and analyzed using FlowJo software (Tree Star Inc.). Splenocytes (6 × 107 cells/mouse) or isolated CD8α+ T cells (3 × 106 cells/
mouse) were intravenously injected into C57BL/6J mice.
Immunohistochemistry. Slides were incubated with FOXP3+, CD4+,
or CD8+ (Abcam; 1:100) at 4°C overnight. TSA Biotin (PerkinElmer) was
used for signal amplification. The Zeiss A1 Scope, Axiocam ICc5, and
Zeiss efficient navigation software (Zeiss) were used for imaging slides
(10–20 fields/tumor). Immune cells per field were quantified via ImageJ.
LC-MS/MS. Plasma from preoperative ketorolac-treated and control mice after LLC resection was analyzed as described (99), with a
Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector
(Shimadzu Corp.) paired with a QTrap 6500 (ABSciex).
scRNA-Seq analysis. Spleens from control and preoperative ketorolac-treated mice at 7 days after LLC resection were processed using the
10× genomics approach. Single-cell libraries were prepared using the
Chromium 3′ reagent kit v2 and sequenced using NextSeq 500 platform to generate approximately 50,000 reads/cell. scRNA-Seq data
after standard quality control was aligned to the reference genome
(mm10) using the 10× Cell Ranger pipeline. Preprocessed and filtered
normalized data were subjected to unsupervised analysis using PCA
(Seurat v2.0 Bioconductor package; ref. 100) to identify principal
components with significant variation that was used as input for tSNE
analysis (101) to determine overall relationship among cells. Cells
with similar transcriptome profiles were clustered together, and the
clusters were subsequently annotated to different cell types based on
expression of specific transcripts, e.g., T cells (Cd3d+), B cells (Cd19+,
Cd79a+, C79b+, etc.). Transcripts significantly associated with a particular cell type were identified by comparing the expression profile of
the target cell with the rest of the cells using nonparametric Wilcox’s
rank test (P < 0.01) and fold change (>1.2).
Identification of treatment-altered genes and pathways in specific cell
types. To determine the effect of treatment on specific cell types, comparative analysis of cell abundance was performed on the control and
ketorolac-treated samples. Comparative analysis of the transcriptome
profiles of each cell type between ketorolac-treated and control groups
was performed using a linear model for microarray analysis approach in
R language (102). Pathways/Functions enrichment and systems biology
analyses using the Ingenuity Pathway Analysis software package (IPA
9.0; QIAGEN) were performed on transcripts that were significantly
associated with different T cell and granulocyte clusters or differentially
expressed in the same cell types between treatment and control groups.
Statistic. For in vivo experiments, Student’s t test and ANOVA
were utilized. Student’s t test was utilized to evaluate significance of
in vitro experiments. The Kolmogorov-Smirnov test was used to evaluate the assumption of normality of continuous variables, and no significant departures from normality were detected. Summary data are
reported as mean ± SEM. Longitudinal tumor growth data were analyzed using 2-factor repeated-measures mixed effects ANOVA with
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the Greenhouse-Geisser F-test to assess overall group differences
followed by Tukey’s post hoc comparisons, where treatment was considered the between-subjects factor and serial tumor measurements
the within-subjects factor. One-way ANOVA was used to compare the
groups with respect to cytokines and biomarker variables. Survival
after tumor resection was analyzed using the Kaplan-Meier product-
limit model with the log-rank test to evaluate survival differences over
time between treatment groups. P values of less than 0.05 were considered statistically significant.
Study approval. Animal studies were approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess
Medical Center.
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